FDA Approves New Oral Treatment for Dermatomyositis

The U.S. FDA has approved the first oral medication specifically for adults with dermatomyositis, a rare autoimmune inflammatory disease affecting muscles and skin. This regulatory decision introduces a new treatment option for patients managing this condition.